Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK to invest in three U.K. facilities
by Rick Mullin
August 1, 2016
| A version of this story appeared in
Volume 94, Issue 31
Britain’s decision to exit the European Union isn’t stopping GlaxoSmithKline from deciding to invest more than $350 million at three of its U.K. sites to boost production of new respiratory therapies and biologic medicines. GSK, which employs about 6,000 at nine U.K. manufacturing locations, will expand in Barnard Castle in County Durham, England; Montrose in Angus, Scotland; and Ware in Hertfordshire, England. The company says most of the products will be exported around the world.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter